Polyneuropathy and Polyclonal Gammopathy
Polyneuropathy and Polyclonal Gammopathy
Source: Gorson KC, et al. Prevalence of polyclonal gammopathy in polyneuropathy. Neurology 1997;49:1747.
Ten percent of patients with idiopathic poly-neuropathy have a monoclonal gammopathy, compared to 2.5% of patients with polyneuropathy due to a secondary cause and 0.1-3% of the general population (Kelly JJ. Muscle Nerve 1985;8:138-150). Uncovering a monoclonal protein clearly has significant implications for diagnosis and therapy (Latov NL. Ann Neurol 1995;37 [S1]:S32-S42). Polyclonal gammopathies (PG), on the other hand, have no such significance. Among patients with chronic inflammatory demyelinating polyneuropathy (CIDP) (n = 76), chronic idiopathic axonal neuropathy (n = 69), diabetic polyneuropathy (n = 63), acute ischemic stroke (n = 63), radiculopathy (n = 21), headache (n = 23), depression (n = 7), TIA (n = 6), dementia (n = 6), dizziness (n = 3), other neurologic disorders (n = 17), and 90 healthy blood donors, the prevalence of PG in CIDP was similar to that in diabetic neuropathy and other neurologic disorders. No specific relationship links PG and polyneuropathy. -mr
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.